OP Asset Management Ltd Buys New Stake in United Therapeutics Corporation $UTHR

OP Asset Management Ltd bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 1st quarter, Holdings Channel reports. The firm bought 4,588 shares of the biotechnology company’s stock, valued at approximately $2,721,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Leuthold Group LLC increased its stake in United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after buying an additional 3,126 shares during the period. UBS Group AG raised its position in shares of United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after buying an additional 70,445 shares in the last quarter. Perpetual Ltd acquired a new stake in shares of United Therapeutics in the 4th quarter worth approximately $1,059,000. SG Americas Securities LLC lifted its stake in shares of United Therapeutics by 88.6% in the 4th quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock worth $13,136,000 after acquiring an additional 12,663 shares during the period. Finally, Brookstone Capital Management boosted its holdings in shares of United Therapeutics by 25.4% in the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock valued at $3,227,000 after acquiring an additional 1,342 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several recent analyst reports. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Price Performance

Shares of UTHR opened at $542.66 on Friday. The firm’s 50 day moving average is $561.23 and its 200-day moving average is $525.58. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The stock has a market capitalization of $23.04 billion, a P/E ratio of 20.03, a P/E/G ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the company earned $6.63 earnings per share. As a group, equities research analysts forecast that United Therapeutics Corporation will post 26.49 EPS for the current fiscal year.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,540,358.40. This represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 643,218 shares of company stock valued at $363,705,304 over the last quarter. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.